Fariborz Kamal
President at 4D MOLECULAR THERAPEUTICS, INC.
Net worth: 139 815 $ as of 30/04/2024
Fariborz Kamal active positions
| Companies | Position | Start | End |
|---|---|---|---|
| 4D MOLECULAR THERAPEUTICS, INC. | Chief Operating Officer | 01/02/2020 | - |
| President | 23/09/2022 | - | |
| Chief Tech/Sci/R&D Officer | 01/10/2018 | 23/09/2022 |
Career history of Fariborz Kamal
Former positions of Fariborz Kamal
| Companies | Position | Start | End |
|---|---|---|---|
| AVEXIS INC | Corporate Officer/Principal | 01/05/2017 | 01/08/2018 |
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | 01/05/2015 | 01/04/2017 |
| INTERMUNE INC | Corporate Officer/Principal | 01/01/2013 | 01/03/2015 |
Training of Fariborz Kamal
| San Jose State University | Undergraduate Degree |
| American University | Doctorate Degree |
Statistics
International
| United States | 7 |
Operational
| Corporate Officer/Principal | 3 |
| Chief Operating Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| 4D MOLECULAR THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Fariborz Kamal
- Experience
